While gabapentin (Neurontin) is now used in a wide variety of clinical settings — for epilepsy, pain management, restless leg syndrome, anxiety, and sleep disturbance – there is relatively little information regarding its reproductive safety. [...]
Over the last few years, we have reported on several studies which have suggested an increased risk of certain types of cardiovascular malformations among children exposed to selective serotonin reuptake inhibitors (SSRIs) during pregnancy. The first reports [...]
Second-generation or “atypical” antipsychotics, such as olanzapine (Zyprexa), aripiprazole (Abilify), and risperidone (Risperdal), are used far more frequently than are the first-generation or “typical” antipsychotics, such as haloperidol (Haldol). This is largely because the newer [...]
Many women experience some degree of sleep disturbance during pregnancy. For a significant number of women, the sleep disruption may be so severe as to require some type of intervention. In a previous post, we discussed the use of different types of medications to treat insomnia during pregnancy. While these drugs are highly effective, many women with sleep problems inquire about the use of “natural” agents, such as melatonin, during pregnancy.
For many women with bipolar disorder, lamotrigine (Lamictal) is an effective mood stabilizer. Given its relatively favorable reproductive safety profile, lamotrigine is a reasonable option for women who require treatment with a mood stabilizer during pregnancy.
You can find a more recent post on this topic here: Venlafaxine and Duloxetine: Pooled Analysis Shows No Increase in Risk of Malformations We receive a fair number of questions on the use of duloxetine [...]
In the developing baby, iodine is necessary for thyroid function and normal brain development. According to a recent Lancet study, even children born to women with mild-to-moderate iodine deficiency during pregnancy are at increased risk for lower IQ and reading ability (assessed at age 9). The most severe effects were observed among children born to women with severe deficiency.
While we have adequate data to support the use of SSRI antidepressants during pregnancy, there is less data regarding other classes of antidepressants. A new case series documents the outcomes of infants exposed to mirtazapine (Remeron).
This is a paper I missed from 2014, but I think this study adds some important information to the review we posted on topiramate a few weeks ago.
Topiramate (TPM, marketed as Topamax) is an antiepileptic drug which is also used for migraine prophylaxis, weight loss, and, less commonly, as a mood stabilizer. Over the last few years we have seen several studies suggesting an increased risk of oral clefts in infants exposed to topiramate during the first trimester of pregnancy. You can read more about those studies here:
